Detection_NN and_CC Characterization_NN of_IN Hepatitis_NP C_NP Virus_NP RNA_NP in_IN Seminal_NP Plasma_NP and_CC Spermatozoon_NP Fractions_NNS of_IN Semen_NP from_IN Patients_NPS Attempting_NP Medically_NP Assisted_NP Conception_NP To_TO investigate_VB the_DT risk_NN of_IN transmission_NN of_IN hepatitis_NP C_NP virus_NN (_( HCV_NP )_) via_IN semen_NN in_IN assisted_VBN reproduction_NN techniques_NNS ,_, semen_NN samples_NNS from_IN 32_CD men_NNS chronically_RB infected_VBN with_IN HCV_NP attending_VBG a_DT center_NN for_IN assisted_VBN procreation_NN were_VBD tested_VBN for_IN HCV_NP RNA_NP by_IN a_DT reverse_JJ transcription-PCR_NN protocol_NN by_IN using_VBG a_DT modified_JJ version_NN of_IN the_DT Cobas_NP AMPLICOR_NP HCV_NP assay_NN (_( version_NN 2.0_CD ;_: Roche_NP Diagnostics_NP )_) ._SENT The_DT sensitivity_NN of_IN the_DT test_NN was_VBD 40_CD copies/ml_NN ._SENT Four_CD of_IN 32_CD seminal_JJ plasma_NN samples_NNS (_( 12.5_CD %_NN )_) were_VBD found_VBN to_TO be_VB positive_JJ for_IN the_DT presence_NN of_IN HCV_NP RNA_NP ._SENT The_DT median_JJ HCV_NP load_NN in_IN blood_NN was_VBD significantly_RB higher_JJR in_IN patients_NNS who_WP were_VBD found_VBN to_TO be_VB positive_JJ for_IN the_DT presence_NN of_IN HCV_NP RNA_NP in_IN semen_NN than_IN in_IN those_DT who_WP tested_VBD negative_JJ (_( P_NN =_SYM 0.02_CD )_) ._SENT In_IN one_CD man_NN ,_, seven_CD consecutive_JJ seminal_JJ plasma_NN samples_NNS tested_VBD positive_JJ for_IN HCV_NP RNA_NP ,_, as_RB did_VBD two_CD consecutive_JJ motile_JJ spermatozoon_NN fractions_NNS ;_: the_DT corresponding_JJ fractions_NNS obtained_VBN after_IN migration_NN of_IN the_DT spermatozoa_NNS remained_VBD negative_JJ ._SENT Despite_IN the_DT absence_NN of_IN the_DT proven_JJ infectivity_NN of_IN virus_NN in_IN semen_NN samples_NNS that_WDT test_VBP positive_JJ for_IN HCV_NP RNA_NP ,_, these_DT findings_NNS highlight_VB the_DT fact_NN that_IN seminal_JJ fluid_NN may_MD exhibit_VB prolonged_JJ HCV_NP RNA_NP excretion_NN ._SENT The_DT usefulness_NN of_IN HCV_NP RNA_NP detection_NN in_IN both_DT seminal_JJ plasma_NN and_CC spermatozoon_NN fractions_NNS before_IN the_DT start_NN of_IN a_DT program_NN of_IN medically_RB assisted_VBN reproduction_NN in_IN couples_NNS in_IN whom_WP the_DT male_JJ partner_NN is_VBZ chronically_RB infected_VBN with_IN HCV_NP would_MD need_VB to_TO be_VB evaluated_VBN prospectively_RB with_IN a_DT larger_JJR population_NN of_IN subjects_NNS exhibiting_VBG HCV_NP RNA_NP in_IN their_PP$ semen_NN ._SENT The_DT risk_NN of_IN transmission_NN of_IN hepatitis_NP C_NP virus_NN (_( HCV_NP )_) via_IN seminal_JJ fluid_NN is_VBZ still_RB much_RB debated_VBN ,_, especially_RB in_IN assisted_VBN reproductive_JJ techniques_NNS (_( ART_NP )_) ._SENT Even_RB though_IN the_DT rate_NN of_IN HCV_NP transmission_NN by_IN the_DT sexual_JJ route_NN has_VBZ been_VBN found_VBN to_TO be_VB low_JJ ,_, the_DT use_NN of_IN spermatozoa_NNS from_IN men_NNS chronically_RB infected_VBN with_IN HCV_NP in_IN ART_NP can_MD lead_VB to_TO a_DT theoretical_JJ risk_NN of_IN contamination_NN for_IN the_DT female_JJ partner_NN ,_, for_IN the_DT technicians_NNS dealing_VBG with_IN ART_NN ,_, and_CC perhaps_RB for_IN the_DT artificially_RB conceived_VBN embryos_NNS of_IN the_DT couple_NN or_CC of_IN other_JJ couples_NNS treated_VBN at_IN the_DT same_JJ time_NN or_CC stored_VBD in_IN the_DT same_JJ container_NN ._SENT The_DT management_NN of_IN HCV-infected_JJ men_NNS enrolled_VBN in_IN programs_NNS of_IN medically_RB assisted_VBN reproduction_NN is_VBZ highly_RB dependent_JJ upon_IN the_DT definition_NN of_IN standardized_JJ protocols_NNS of_IN detection_NN of_IN HCV_NP RNA_NP in_IN semen_NN ._SENT Actually_RB ,_, although_IN previous_JJ studies_NNS have_VBP reported_VBN the_DT presence_NN of_IN HCV_NP RNA_NP in_IN seminal_JJ plasma_NN of_IN men_NNS chronically_RB infected_VBN with_IN HCV_NP and_CC coinfected_JJ or_CC not_RB coinfected_JJ with_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) ,_, other_JJ investigators_NNS have_VBP found_VBN the_DT opposite_JJ pattern_NN ._SENT Those_DT contradictory_JJ results_NNS could_MD be_VB explained_VBN ,_, at_IN least_JJS in_IN part_NN ,_, by_IN the_DT heterogeneity_NN of_IN the_DT populations_NNS studied_VBN and_CC by_IN the_DT diversity_NN and_CC the_DT poor_JJ standardization_NN of_IN the_DT techniques_NNS used_VBN for_IN the_DT extraction_NN of_IN RNA_NP from_IN semen_NN and_CC for_IN the_DT reverse_JJ transcription_NN (RT)-PCR_NN protocols_NNS ._SENT Moreover_RB ,_, the_DT cellular_JJ fractions_NNS of_IN semen_NN ,_, particularly_RB the_DT motile_JJ spermatozoa_NNS ,_, have_VBP been_VBN poorly_RB investigated_VBN for_IN the_DT presence_NN of_IN HCV_NP ._SENT We_PP report_VBP herein_RB on_IN the_DT detection_NN of_IN HCV_NP RNA_NP in_IN seminal_JJ plasma_NN and_CC ,_, for_IN the_DT first_JJ time_NN ,_, in_IN the_DT motile_JJ spermatozoon_NN fractions_NNS of_IN semen_NN from_IN men_NNS chronically_RB infected_VBN with_IN HCV_NP and_CC attempting_VBG medically_RB assisted_VBN reproduction_NN ._SENT Patients_NNS ._SENT |_SYM Thirty-two_NP male_JJ patients_NNS (_( mean_JJ age_NN ,_, 39_CD years_NNS ;_: age_NN range_NN ,_, 32_CD to_TO 52_CD years_NNS )_) entering_VBG a_DT program_NN of_IN ART_NP were_VBD included_VBN in_IN the_DT study_NN after_IN they_PP gave_VBD their_PP$ fully_RB informed_VBN written_JJ consent_NN ._SENT All_DT men_NNS tested_VBD positive_JJ for_IN HCV_NP RNA_NP in_IN blood_NN by_IN RT-PCR_NP and_CC were_VBD negative_JJ for_IN HIV_NP antibodies_NNS and_CC hepatitis_NP B_NP surface_NN antigen_NN ._SENT The_DT risk_NN factors_NNS for_IN HCV_NP contamination_NN were_VBD transfusion_NN of_IN blood_NN products_NNS in_IN 4_CD men_NNS (_( 12.5_CD %_NN )_) ,_, hemophilia_NN in_IN 2_CD men_NNS (_( 6.3_CD %_NN )_) ,_, intravenous_JJ drug_NN addiction_NN in_IN 8_CD men_NNS (_( 25_CD %_NN )_) ,_, and_CC unidentified_JJ in_IN 18_CD men_NNS (_( 56.2_CD %_NN )_) ._SENT No_DT patient_NN had_VBD received_VBN any_DT antiviral_JJ drugs_NNS for_IN chronic_JJ hepatitis_NP C._NP Sequential_NP samples_NNS of_IN semen_NN were_VBD obtained_VBN from_IN nine_CD men_NNS :_: seven_CD men_NNS each_DT gave_VBD two_CD samples_NNS (_( mean_JJ delay_NN between_IN collection_NN of_IN the_DT two_CD samples_NNS ,_, 12.4_CD +-_NN 8_CD months_NNS )_) ,_, one_CD man_NN gave_VBD three_CD sequential_JJ samples_NNS within_IN 8_CD months_NNS ,_, and_CC one_CD man_NN gave_VBD seven_CD successive_JJ samples_NNS within_IN 11_CD months_NNS ._SENT Samples_NNS ._SENT |_SYM Plasma_NP samples_NNS were_VBD separated_VBN from_IN blood_NN by_IN centrifugation_NN and_CC frozen_VBN at_IN -80C_NN until_IN use_NN ._SENT After_IN 3_CD days_NNS of_IN sexual_JJ abstinence_NN ,_, semen_NN samples_NNS were_VBD obtained_VBN by_IN masturbation_NN into_IN a_DT sterile_JJ container_NN and_CC were_VBD processed_VBN within_IN 2_CD h_NN of_IN ejaculation_NN ._SENT One_CD milliliter_NN of_IN the_DT semen_NN sample_NN was_VBD centrifuged_VBN at_IN 800_CD x_NN g_NN for_IN 10_CD min_NN ,_, and_CC the_DT seminal_JJ plasma_NN was_VBD separated_VBN from_IN the_DT cell_NN pellet_NN and_CC stored_VBD at_IN -80C_NN until_IN further_JJR use_NN (_( fraction_NN 1_CD )_) ._SENT Another_DT milliliter_NN was_VBD submitted_VBN to_TO centrifugation_NN through_IN a_DT three-layer_JJ discontinuous_JJ Percoll_NP (_( Pharmacia_NP ,_, Uppsala_NP ,_, Sweden_NP )_) gradient_NN (_( 3_CD ml_NN of_IN 50_CD ,_, 70_CD ,_, and_CC 90_CD %_NN Percoll_NP ,_, respectively_RB )_) ;_: the_DT motile_JJ spermatozoa_NNS were_VBD recovered_VBN from_IN the_DT 90_CD %_NN fraction_NN ,_, observed_VBN by_IN microscopic_JJ examination_NN for_IN number_NN and_CC to_TO check_VB for_IN the_DT absence_NN of_IN white_JJ blood_NN cell_NN contamination_NN ,_, and_CC kept_VBD frozen_VBN at_IN -80C_NN as_IN aliquots_NNS of_IN 500,000_CD cells_NNS until_IN use_NN (_( fraction_NN 2_CD )_) ._SENT For_IN one_CD patient_NN ,_, 0.5_CD ml_NN of_IN sterile_JJ synthetic_JJ medium_NN (_( BM1_NP ;_: Ellios_NP Biotek_NP Laboratories_NPS ,_, Paris_NP ,_, France_NP )_) used_VBD for_IN in_IN vitro_NN cell_NN culture_NN was_VBD layered_VBN on_IN the_DT top_NN of_IN the_DT 90_CD %_NN fraction_NN obtained_VBN after_IN Percoll_NP selection_NN ;_: after_IN incubation_NN for_IN 45_CD min_NN at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ incubator_NN ,_, the_DT upper_JJ 0.5_CD ml_NN was_VBD carefully_RB removed_VBN and_CC the_DT spermatozoa_NNS were_VBD counted_VBN ._SENT This_DT "_`` swim-up_JJ "_'' fraction_NN was_VBD kept_VBN frozen_VBN at_IN -80C_NN as_IN aliquots_NNS of_IN 500,000_CD cells_NNS until_IN use_NN (_( fraction_NN 3_CD )_) ._SENT Detection_NN of_IN HCV_NP RNA_NP in_IN blood_NN plasma_NN ._SENT |_SYM The_DT qualitative_JJ detection_NN of_IN HCV_NP RNA_NP in_IN blood_NN plasma_NN was_VBD performed_VBN by_IN the_DT Cobas_NP AMPLICOR_NP HCV_NP assay_NN (_( version_NN 2.0_CD ;_: Roche_NP Diagnostics_NP ,_, Meylan_NP ,_, France_NP )_) ,_, according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT The_DT quantification_NN of_IN HCV_NP RNA_NP was_VBD achieved_VBN by_IN the_DT Cobas_NP AMPLICOR_NP HCV_NP Monitor_NP assay_NN (_( version_NN 2.0_CD ;_: Roche_NP Diagnostics_NP )_) ._SENT Detection_NN of_IN HCV_NP RNA_NP in_IN seminal_JJ plasma_NN (_( fraction_NN 1_CD )_) ._SENT |_SYM The_DT RNA_NP extraction_NN step_NN was_VBD performed_VBN by_IN a_DT protocol_NN modified_VBN from_IN that_DT of_IN the_DT QIAmp_NN viral_JJ RNA_NP kit_NN (_( Qiagen_NP ,_, Courtaboeuf_NP ,_, France_NP )_) ,_, as_RB follows_VBZ :_: 250_CD mul_NN of_IN thawed_VBN fraction_NN 1_CD was_VBD diluted_VBN (_( vol/vol_NN )_) in_IN sterile_JJ water_NN and_CC centrifuged_VBN at_IN 20,000_CD x_NN g_NN for_IN 1_CD h_NN ;_: the_DT supernatant_JJ was_VBD removed_VBN ,_, and_CC the_DT resulting_VBG pellet_NN was_VBD resuspended_VBN in_IN 600_CD mul_NN of_IN AVL_NP lysis_NN buffer_NN (_( Qiagen_NP )_) containing_VBG 6.4_CD mul_NN of_IN the_DT internal_JJ control_NN from_IN the_DT Roche_NP Cobas_NP AMPLICOR_NP assay_NN ._SENT After_IN an_DT incubation_NN step_NN of_IN 10_CD min_NN at_IN room_NN temperature_NN ,_, 600_CD mul_NN of_IN absolute_JJ ethanol_NN was_VBD added_VBN and_CC the_DT whole_JJ mixture_NN was_VBD centrifuged_VBN through_IN a_DT QIAmp_JJ column_NN at_IN 6,000_CD x_NN g_NN for_IN 1_CD min_NN ._SENT After_IN two_CD successive_JJ washing_NN steps_NNS with_IN AW1_JJ buffer_NN for_IN 1_CD min_NN at_IN 6,000_CD x_NN g_NN and_CC AW2_JJ buffer_NN for_IN 3_CD min_NN at_IN 12,000_CD x_NN g_NN ,_, the_DT RNA_NP extracts_VBZ were_VBD removed_VBN from_IN the_DT column_NN by_IN addition_NN of_IN 200_CD mul_NN of_IN AVE_JJ elution_NN buffer_NN and_CC were_VBD centrifuged_VBN at_IN 6,000_CD x_NN g_NN for_IN 1_CD min_NN ._SENT RT_NP and_CC qualitative_JJ PCR_NP were_VBD done_VBN by_IN the_DT Cobas_NP AMPLICOR_NP HCV_NP assay_NN (_( version_NN 2.0_CD )_) according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT The_DT quantification_NN of_IN HCV_NP RNA_NP in_IN seminal_JJ plasma_NN was_VBD carried_VBN out_RP as_RB follows_VBZ :_: the_DT RNA_NP extraction_NN step_NN was_VBD similar_JJ to_TO that_DT for_IN the_DT qualitative_JJ protocol_NN ,_, except_IN that_WDT the_DT volume_NN of_IN elution_NN buffer_NN was_VBD 400_CD mul_NN instead_RB of_IN 1,000_CD mul_NN ._SENT RT_NP and_CC quantitative_JJ PCR_NP were_VBD done_VBN by_IN the_DT Cobas_NP AMPLICOR_NP Monitor_NP HCV_NP assay_NN (_( version_NN 2.0_CD )_) as_IN recommended_VBN by_IN the_DT manufacturer_NN ._SENT The_DT final_JJ result_NN was_VBD expressed_VBN as_IN the_DT number_NN of_IN copies_NNS per_IN milliliter_NN with_IN reference_NN to_TO the_DT volume_NN of_IN 250_CD mul_NN used_VBN in_IN the_DT extraction_NN step_NN ._SENT The_DT sensitivities_NNS of_IN the_DT qualitative_JJ and_CC quantitative_JJ assays_NNS were_VBD determined_VBN by_IN using_VBG serial_JJ 2-fold_JJ dilutions_NNS (_( from_IN 160_CD to_TO 10_CD copies/ml_NN )_) or_CC 10-fold_NN dilutions_NNS (_( from_IN 10,000_CD to_TO 10_CD copies/ml_NN )_) ,_, respectively_RB ,_, in_IN HCV-negative_JJ seminal_JJ plasma_NN of_IN blood_NN plasma_NN from_IN an_DT HCV-infected_JJ patient_NN ,_, which_WDT had_VBD been_VBN quantified_VBN previously_RB by_IN the_DT Cobas_NP AMPLICOR_NP 4CV_NP Monitor_NP assay_NN ;_: then_RB ,_, each_DT dilution_NN was_VBD extracted_VBN and_CC tested_VBN in_IN six_CD independent_JJ experiments_NNS ._SENT Detection_NN of_IN HCV_NP RNA_NP in_IN spermatozoon_NN fractions_NNS ._SENT |_SYM Twenty-five_NP fractions_NNS 2_CD (_( motile_NN spermatozoa_NNS )_) from_IN 14_CD patients_NNS and_CC four_CD fractions_NNS 3_CD (_( swim-up_NN spermatozoa_NNS )_) from_IN 1_CD patient_NN were_VBD tested_VBN for_IN the_DT presence_NN of_IN HCV_NP RNA_NP ._SENT The_DT RNA_NP extraction_NN was_VBD performed_VBN by_IN combining_VBG a_DT lysis_NN step_NN with_IN proteinase_NN K_NP (_( 50_CD mg/ml_NN )_) by_IN use_NN of_IN the_DT RNAeasy_NP Mini_NP kit_NN (_( Qiagen_NP )_) ._SENT With_IN reference_NN to_TO the_DT standard_JJ Qiagen_NP protocol_NN ,_, an_DT additional_JJ step_NN of_IN elution_NN of_IN the_DT column_NN was_VBD performed_VBN with_IN the_DT first_JJ eluate_NN ._SENT The_DT internal_JJ control_NN of_IN the_DT Cobas_NP AMPLICOR_NP HCV_NP kit_NN was_VBD diluted_VBN 1:16_CD in_IN 50_CD mul_NN of_IN the_DT column_NN eluate_NN ._SENT RT_NP and_CC qualitative_JJ PCR_NP were_VBD done_VBN according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT In_IN addition_NN ,_, a_DT test_NN with_IN an_DT extraction_NN control_NN was_VBD performed_VBN by_IN RT-PCR_NP amplification_NN of_IN an_DT intron-containing_JJ region_NN of_IN the_DT protamin_NN 2_CD gene_NN ,_, as_RB described_VBN previously_RB ._SENT Use_NN of_IN a_DT threshold_NN of_IN 500,000_CD cells_NNS in_IN the_DT PCR_NP experiments_NNS was_VBD justified_VBN by_IN the_DT reproductive_JJ amplification_NN of_IN the_DT control_NN gene_NN at_IN this_DT cell_NN concentration_NN but_CC not_RB at_IN a_DT lower_JJR one_CD ._SENT HCV_NP genotyping_NN ._SENT |_SYM The_DT genotypes_NNS of_IN the_DT HCV_NP strains_NNS in_IN blood_NN and_CC seminal_JJ samples_NNS were_VBD determined_VBN by_IN sequencing_VBG the_DT 5_CD '_POS noncoding_JJ region_NN by_IN the_DT TruGene_NP HCV_NP assay_NN (_( Visible_NP Genetics_NP ,_, Espinay_NP sur_NP Orge_NP ,_, France_NP )_) ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Quantitative_JJ and_CC qualitative_JJ values_NNS were_VBD compared_VBN by_IN Student_NP 's_POS t_NN test_NN and_CC the_DT chi-square_NN test_NN ,_, respectively_RB ._SENT The_DT threshold_NN for_IN a_DT significant_JJ value_NN was_VBD 0.05_CD ._SENT Detection_NN of_IN HCV_NP RNA_NP in_IN blood_NN and_CC seminal_JJ plasma_NN ._SENT |_SYM All_DT 32_CD patients_NNS included_VBN in_IN the_DT study_NN were_VBD positive_JJ for_IN the_DT presence_NN of_IN HCV_NP RNA_NP in_IN blood_NN plasma_NN ._SENT Their_PP$ mean_JJ viral_JJ load_NN was_VBD 5.97_CD +-_NN 0.51_CD log_NN copies/ml_NN (_( range_NN ,_, 4.97_CD to_TO 7.34_CD log_NN copies/ml_NN )_) ._SENT The_DT genotypes_NNS of_IN the_DT HCV_NP strains_NNS detected_VBD in_IN the_DT blood_NN samples_NNS of_IN 24_CD subjects_NNS were_VBD distributed_VBN as_RB follows_VBZ :_: 1_CD (_( two_CD patients_NNS )_) ,_, 1a_NP (_( seven_CD patients_NNS )_) ,_, 1b_NP (_( four_CD patients_NNS )_) ,_, 2_CD (_( three_CD patients_NNS )_) ,_, 3_CD (_( one_CD patient_NN )_) ,_, 3a_NP (_( six_CD patients_NNS )_) ,_, and_CC 4_CD (_( one_CD patient_NN )_) ._SENT PCR_NP inhibitors_NNS were_VBD detected_VBN in_IN only_RB 1_CD of_IN 32_CD (_( 3.3_CD %_NN )_) seminal_JJ plasma_NN specimens_NNS ,_, but_CC they_PP were_VBD not_RB detected_VBN after_IN the_DT seminal_JJ sample_NN was_VBD diluted_VBN 1:2_CD in_IN RNase-free_JJ water_NN ._SENT The_DT sensitivity_NN of_IN the_DT qualitative_JJ assay_NN ,_, determined_VBN in_IN six_CD independent_JJ experiments_NNS as_IN the_DT lowest_JJS dilution_NN found_VBD to_TO be_VB positive_JJ in_IN all_PDT the_DT experiments_NNS ,_, was_VBD 40_CD copies/ml_NN (_( 1.6_CD log_NN copies/ml_NN )_) ._SENT By_IN using_VBG the_DT same_JJ algorithm_NN ,_, the_DT sensitivity_NN of_IN the_DT quantitative_JJ assay_NN was_VBD 100_CD copies/ml_NN (_( 2_CD log_NN copies/ml_NN )_) ._SENT Seminal_JJ plasma_NN samples_NNS from_IN 4_CD of_IN 32_CD patients_NNS (_( 12.5_CD %_NN )_) were_VBD found_VBN to_TO be_VB positive_JJ for_IN HCV_NP RNA_NP by_IN the_DT qualitative_JJ test_NN ._SENT The_DT four_CD patients_NNS had_VBD been_VBN infected_VBN through_IN intravenous_JJ drug_NN abuse_NN ._SENT The_DT seminal_JJ viral_JJ loads_NNS of_IN these_DT four_CD patients_NNS are_VBP listed_VBN in_IN Table_NP ._SENT The_DT difference_NN in_IN viral_JJ loads_NNS between_IN blood_NN and_CC semen_NN ranged_VBN from_IN 2.83_CD to_TO more_JJR than_IN 5.34_CD log_NN copies/ml_NN ._SENT The_DT mean_JJ blood_NN viral_JJ load_NN was_VBD significantly_RB higher_JJR in_IN patients_NNS positive_JJ for_IN HCV_NP RNA_NP in_IN semen_NN than_IN in_IN those_DT negative_JJ for_IN HCV_NP RNA_NP in_IN semen_NN (_( 6.52_CD +-_NN 0.55_CD versus_CC 5.88_CD +-_NN 0.46_CD log_NN copies/ml_NN [_SYM P_NN =_SYM 0.02_CD ]_SYM )_) ._SENT For_IN the_DT four_CD patients_NNS positive_JJ for_IN HCV_NP RNA_NP in_IN semen_NN ,_, the_DT same_JJ HCV_NP genotype_NN was_VBD found_VBN in_IN both_DT blood_NN and_CC seminal_JJ plasma_NN ._SENT Analysis_NN of_IN sequential_JJ seminal_JJ samples_NNS ._SENT |_SYM Successive_JJ seminal_JJ specimens_NNS were_VBD obtained_VBN from_IN nine_CD patients_NNS ._SENT Of_IN the_DT seven_CD subjects_NNS who_WP each_DT provided_VBN two_CD seminal_JJ samples_NNS ,_, the_DT detection_NN of_IN HCV_NP RNA_NP in_IN seminal_JJ plasma_NN was_VBD found_VBN to_TO be_VB unchanged_JJ over_IN time_NN in_IN six_CD patients_NNS (_( negative_JJ in_IN five_CD patients_NNS and_CC positive_JJ in_IN one_CD patient_NN )_) ;_: in_IN the_DT remaining_VBG patient_NN ,_, HCV_NP RNA_NP was_VBD detected_VBN only_RB in_IN the_DT first_JJ seminal_JJ sample_NN ._SENT For_IN one_CD man_NN ,_, three_CD sequential_JJ samples_NNS ,_, collected_VBN within_IN 8_CD months_NNS ,_, tested_VBD negative_JJ for_IN HCV_NP RNA_NP ._SENT For_IN another_DT man_NN (_( patient_NN 3_CD in_IN Table_NN )_) who_WP provided_VBD seven_CD successive_JJ samples_NNS within_IN 11_CD months_NNS ,_, all_PDT the_DT seminal_JJ plasma_NN fractions_NNS tested_VBD positive_JJ for_IN HCV_NP RNA_NP (_( with_IN the_DT quantities_NNS ranging_VBG from_IN <100_NN to_TO 860_CD copies/ml_NN )_) ._SENT Detection_NN of_IN HCV_NP RNA_NP in_IN spermatozoon_NN fractions_NNS ._SENT |_SYM The_DT corresponding_JJ motile_JJ spermatozoa_NNS (_( fraction_NN 2_LS )_) collected_VBN from_IN the_DT four_CD patients_NNS whose_WP$ seminal_JJ plasma_NN was_VBD HCV_NP RNA_NP positive_NN were_VBD tested_VBN for_IN HCV_NP RNA_NP ._SENT In_IN addition_NN ,_, 15_CD fractions_NNS 2_CD belonging_NN to_TO 10_CD patients_NNS whose_WP$ seminal_JJ plasma_NN was_VBD negative_JJ for_IN HCV_NP RNA_NP were_VBD tested_VBN ._SENT All_DT fractions_VBZ 2_CD tested_VBN remained_VBD negative_JJ for_IN HCV_NP RNA_NP with_IN the_DT exception_NN of_IN two_CD of_IN five_CD samples_NNS collected_VBN from_IN patient_JJ 3_CD ,_, in_IN which_WDT HCV_NP RNA_NP was_VBD persistently_RB detected_VBN in_IN seminal_JJ plasma_NN from_IN July_NP 2000_CD to_TO May_NP 2001_CD ._SENT Fraction_NN 2_CD of_IN patient_JJ 3_CD was_VBD positive_JJ for_IN HCV_NP RNA_NP only_RB for_IN a_DT short_JJ time_NN corresponding_JJ to_TO the_DT first_JJ 2_CD weeks_NNS of_IN April_NP 2001_CD ;_: moreover_RB ,_, the_DT four_CD samples_NNS of_IN fraction_NN 3_CD (_( swim-up_NN spermatozoa_NNS )_) from_IN patient_JJ 3_CD tested_VBD negative_JJ during_IN the_DT course_NN of_IN the_DT study_NN ._SENT The_DT efficiency_NN of_IN the_DT extraction_NN step_NN with_IN the_DT spermatozoon_NN fractions_NNS was_VBD evaluated_VBN by_IN the_DT detection_NN of_IN protamin_NN 2_CD gene_NN RNA_NP ,_, and_CC all_DT specimens_NNS tested_VBN were_VBD found_VBN to_TO be_VB positive_JJ ._SENT In_IN addition_NN ,_, cell_NN samples_NNS were_VBD found_VBN to_TO be_VB positive_JJ for_IN the_DT internal_JJ control_NN ,_, demonstrating_VBG the_DT absence_NN of_IN PCR_NP inhibitors_NNS in_IN these_DT fractions_NNS ._SENT Assays_NNS after_IN assisted_VBN reproduction_NN ._SENT |_SYM Eleven_NP attempts_NNS at_IN medically_RB assisted_VBN reproduction_NN were_VBD performed_VBN for_IN couples_NNS for_IN whom_WP the_DT male_JJ partner_NN tested_VBD negative_JJ for_IN the_DT presence_NN of_IN HCV_NP RNA_NP in_IN seminal_JJ plasma_NN ._SENT Five_CD women_NNS became_VBD pregnant_JJ ,_, with_IN the_DT occurrence_NN of_IN two_CD singleton_NN births_NNS and_CC with_IN one_CD set_NN of_IN triplets_NNS and_CC two_CD sets_NNS of_IN twins_NNS being_VBG born_VBN ._SENT The_DT blood_NN of_IN the_DT nine_CD babies_NNS tested_VBD negative_JJ for_IN HCV_NP RNA_NP at_IN birth_NN ,_, and_CC the_DT babies_NNS remained_VBD uninfected_JJ at_IN least_JJS 6_CD months_NNS later_RBR ._SENT For_IN patient_JJ 3_CD ,_, given_VBN that_IN HCV_NP RNA_NP was_VBD detected_VBN in_IN all_DT seminal_JJ plasma_NN samples_NNS tested_VBN and_CC in_IN two_CD motile_JJ spermatozoon_NN fractions_NNS ,_, the_DT in_IN vitro_NP fertilization_NN program_NN with_IN fresh_JJ semen_NN was_VBD discontinued_VBN ._SENT When_WRB the_DT motile_JJ spermatozoon_NN fractions_NNS became_VBD negative_JJ ,_, they_PP were_VBD frozen_VBN in_IN specific_JJ highly_RB secure_JJ straws_NNS for_IN future_JJ ART_NNS ._SENT For_IN the_DT three_CD other_JJ patients_NNS whose_WP$ seminal_JJ plasma_NN was_VBD positive_JJ for_IN HCV_NP RNA_NP ,_, the_DT ART_NN were_VBD delayed_VBN ._SENT TABLE_NN 1_CD |_SYM Characteristics_NN of_IN the_DT four_CD men_NNS whose_WP$ seminal_JJ plasma_NN was_VBD positive_JJ for_IN HCV_NP RNA_NP TABLE_NP 2_CD |_SYM Characteristics_NN of_IN patients_NNS whose_WP$ blood_NN was_VBD chronically_RB infected_VBN with_IN HCV_NP according_VBG to_TO presence_NN or_CC absence_NN of_IN HCV_NP RNA_NP in_IN seminal_JJ fluid_NN The_DT overall_JJ results_NNS of_IN this_DT study_NN show_VBP that_IN the_DT seminal_JJ plasma_NN of_IN 4_CD of_IN 32_CD (_( 12.5_CD %_NN )_) subjects_NNS chronically_RB infected_VBN with_IN HCV_NP were_VBD found_VBN to_TO be_VB positive_JJ for_IN HCV_NP RNA_NP by_IN the_DT RT-PCR_NP technique_NN ._SENT Previous_JJ studies_NNS on_IN the_DT same_JJ topic_NN gave_VBD conflicting_JJ results_NNS :_: three_CD failed_VBD to_TO detect_VB any_DT HCV-positive_JJ seminal_JJ sample_NN ,_, and_CC two_CD reported_VBD anecdotal_JJ cases_NNS of_IN HCV-positive_JJ semen_NN ._SENT In_IN addition_NN ,_, two_CD reported_VBD that_IN relatively_RB high_JJ proportions_NNS of_IN patients_NNS were_VBD positive_JJ for_IN HCV_NP RNA_NP in_IN this_DT compartment_NN :_: 8_CD of_IN 21_CD (_( 38_CD %_NN )_) patients_NNS and_CC 4_CD of_IN 20_CD (_( 20_CD %_NN )_) patients_NNS in_IN the_DT studies_NNS of_IN Leruez-Ville_NP et_FW al._FW and_CC Pasquier_NN et_FW al._FW ,_, respectively_RB ._SENT The_DT HIV_NP serological_JJ status_NN is_VBZ an_DT important_JJ point_NN to_TO be_VB addressed_VBN since_IN HIV_NP has_VBZ been_VBN shown_VBN to_TO be_VB a_DT factor_NN that_WDT dramatically_RB enhances_VBZ the_DT pathogenicity_NN of_IN HCV_NP in_IN the_DT livers_NNS of_IN patients_NNS infected_VBN with_IN both_DT viruses_NNS ._SENT Altogether_RB ,_, 35_CD of_IN the_DT 41_CD patients_NNS tested_VBN in_IN the_DT two_CD studies_NNS cited_VBD above_IN were_VBD HIV_NP positive_NN ,_, and_CC 10_CD of_IN them_PP exhibited_VBD HCV_NP RNA_NP in_IN their_PP$ semen_NN ._SENT In_IN comparison_NN ,_, only_RB six_CD HIV-negative_JJ subjects_NNS (_( two_CD of_IN whom_WP were_VBD positive_JJ for_IN HCV_NP RNA_NP in_IN their_PP$ semen_NN )_) were_VBD tested_VBN in_IN the_DT first_JJ study_NN and_CC no_DT HIV-negative_JJ subjects_NNS were_VBD tested_VBN in_IN the_DT second_JJ one_CD ._SENT These_DT small_JJ numbers_NNS of_IN patients_NNS do_VBP not_RB allow_VB statistical_JJ comparison_NN of_IN the_DT prevalence_NN of_IN HCV_NP RNA_NP in_IN the_DT semen_NN of_IN HIV-negative_JJ subjects_NNS ,_, especially_RB since_IN no_DT data_NNS concerning_VBG the_DT selection_NN of_IN patients_NNS were_VBD available_JJ ._SENT Conversely_RB ,_, the_DT 12.5_CD %_NN rate_NN of_IN HCV_NP RNA_NP positivity_NN for_IN the_DT semen_NN of_IN 32_CD consecutive_JJ HIV-negative_JJ subjects_NNS in_IN the_DT present_JJ study_NN seems_VBZ more_JJR representative_NN of_IN the_DT actual_JJ rate_NN of_IN positivity_NN for_IN this_DT compartment_NN ._SENT The_DT threshold_NN of_IN the_DT assay_NN reached_VBD 40_CD copies/ml_NN ,_, with_IN a_DT very_RB low_JJ rate_NN of_IN false-negative_JJ results_NNS due_JJ to_TO the_DT presence_NN of_IN PCR_NP inhibitors_NNS ,_, as_RB demonstrated_VBN by_IN the_DT use_NN of_IN a_DT standardized_JJ commercial_JJ technique_NN that_WDT included_VBD an_DT internal_JJ control_NN ._SENT This_DT high_JJ rate_NN of_IN sensitivity_NN compared_VBN to_TO that_DT of_IN the_DT protocol_NN used_VBN in_IN the_DT standard_JJ AMPLICOR_NP assay_NN with_IN blood_NN samples_NNS can_MD be_VB explained_VBN by_IN the_DT addition_NN of_IN a_DT step_NN consisting_VBG of_IN high-speed_JJ centrifugation_NN of_IN the_DT sample_NN ._SENT It_PP was_VBD close_JJ to_TO the_DT one_CD reported_VBN for_IN seminal_JJ specimens_NNS by_IN Leruez-Ville_NP et_FW al._FW ,_, who_WP used_VBD the_DT same_JJ PCR_NP kit_NN used_VBN in_IN the_DT present_JJ study_NN but_CC a_DT silica-based_JJ extraction_NN technique_NN ._SENT In_IN addition_NN to_TO previous_JJ studies_NNS on_IN the_DT same_JJ topic_NN ,_, this_DT report_NN provides_VBZ several_JJ new_JJ findings_NNS :_: (_( i_NP )_) the_DT amount_NN of_IN viral_JJ RNA_NP in_IN seminal_JJ plasma_NN was_VBD larger_JJR than_IN 500_CD copies/ml_NN in_IN three_CD of_IN the_DT four_CD positive_JJ patients_NNS and_CC was_VBD up_RB to_TO 3,000_CD copies/ml_NN in_IN one_CD patient_NN ;_: (_( ii_NP )_) in_IN all_DT four_CD of_IN these_DT patients_NNS ,_, the_DT genotypes_NNS of_IN the_DT strains_NNS in_IN the_DT blood_NN and_CC semen_NN of_IN the_DT same_JJ patient_NN were_VBD found_VBN to_TO be_VB identical_JJ ;_: and_CC (_( iii_NNS )_) a_DT positive_JJ correlation_NN between_IN the_DT viral_JJ loads_NNS in_IN seminal_JJ plasma_NN and_CC blood_NN was_VBD noted_VBN ._SENT None_NN of_IN these_DT data_NNS describe_VBP the_DT compartmentalization_NN of_IN HCV_NP RNA_NP between_IN seminal_JJ plasma_NN and_CC blood_NN ._SENT They_PP suggest_VBP that_IN the_DT semen_NN of_IN patients_NNS who_WP are_VBP chronically_RB infected_VBN with_IN HCV_NP for_IN a_DT long_JJ time_NN and_CC who_WP exhibit_VBP high_JJ viral_JJ loads_NNS are_VBP more_RBR likely_JJ to_TO be_VB positive_JJ for_IN HCV_NP RNA_NP ;_: similar_JJ findings_NNS have_VBP been_VBN shown_VBN for_IN HIV-infected_JJ patients_NNS ._SENT Another_DT finding_NN original_JJ to_TO this_DT study_NN was_VBD the_DT detection_NN of_IN HCV_NP RNA_NP not_RB only_RB in_IN seminal_JJ plasma_NN but_CC also_RB in_IN spermatozoon_NN fractions_NNS used_VBN in_IN ART_NP ._SENT Relevant_JJ controls_NNS were_VBD used_VBN to_TO validate_VB the_DT extraction_NN and_CC amplification_NN steps_NNS performed_VBN on_IN these_DT cells_NNS :_: for_IN all_DT samples_NNS tested_VBD the_DT RNA_NP of_IN the_DT protamin_NN 2_CD gene_NN was_VBD amplified_VBN and_CC the_DT internal_JJ control_NN of_IN the_DT PCR_NP assay_NN was_VBD positive_JJ ._SENT In_IN one_CD patient_NN whose_WP$ blood_NN and_CC seminal_JJ plasma_NN were_VBD both_DT chronically_RB infected_VBN with_IN HCV_NP ,_, two_CD successive_JJ samples_NNS of_IN the_DT motile_JJ spermatozoon_NN fraction_NN were_VBD found_VBN to_TO be_VB positive_JJ for_IN HCV_NP RNA_NP ,_, whereas_IN the_DT same_JJ test_NN performed_VBN with_IN spermatozoa_NNS corresponding_JJ to_TO the_DT swim-up_NN fractions_NNS was_VBD negative_JJ ._SENT This_DT observation_NN ,_, which_WDT to_TO our_PP$ knowledge_NN has_VBZ never_RB been_VBN described_VBN previously_RB ,_, needs_VBZ discussion_NN ;_: although_IN the_DT possibility_NN that_IN spermatozoa_NNS support_VBP HCV_NP replication_NN cannot_MD be_VB definitively_RB excluded_VBN ,_, the_DT more_RBR valuable_JJ explanation_NN relies_VBZ on_IN the_DT passive_JJ adsorption_NN to_TO the_DT cell_NN membrane_NN of_IN HCV_NP RNA_NP or_CC virions_NNS present_JJ in_IN seminal_JJ plasma_NN ,_, as_RB suggested_VBN by_IN the_DT intermittent_JJ detection_NN of_IN HCV_NP RNA_NP in_IN spermatozoa_NNS and_CC by_IN the_DT absence_NN of_IN RNA_NP in_IN the_DT corresponding_JJ swim-up_NN fraction_NN ._SENT In_IN fact_NN ,_, the_DT adsorption_NN of_IN viral_JJ particles_NNS to_TO cell_NN membranes_NNS could_MD reduce_VB the_DT mobility_NN of_IN the_DT spermatozoa_NNS ,_, as_RB described_VBN previously_RB for_IN cytomegalovirus_NN ._SENT Even_RB though_IN the_DT detection_NN of_IN HCV_NP RNA_NP in_IN fractions_NNS of_IN semen_NN does_VBZ not_RB necessarily_RB imply_VB the_DT presence_NN of_IN replicative_JJ virions_NNS and_CC the_DT infectivity_NN of_IN spermatozoa_NNS via_IN medically_RB assisted_VBN reproduction_NN ,_, our_PP$ results_NNS plead_VB for_IN the_DT reinforcement_NN of_IN precaution_NN measures_NNS for_IN men_NNS whose_WP$ blood_NN is_VBZ chronically_RB infected_VBN with_IN HCV_NP and_CC who_WP are_VBP candidates_NNS for_IN ART_NN ._SENT It_PP is_VBZ suggested_VBN that_IN seminal_JJ plasma_NN be_VB systematically_RB evaluated_VBN for_IN the_DT absence_NN of_IN viral_JJ RNA_NP in_IN order_NN to_TO ensure_VB that_IN ART_NNS are_VBP performed_VBN with_IN samples_NNS free_JJ of_IN HCV_NP RNA_NP ._SENT In_IN those_DT subjects_NNS found_VBD to_TO be_VB positive_JJ ,_, it_PP is_VBZ proposed_VBN that_IN motile_JJ spermatozoa_NNS be_VB investigated_VBN for_IN the_DT presence_NN of_IN HCV_NP RNA_NP and_CC that_DT only_JJ spermatozoon_NN fractions_NNS that_WDT test_VBP negative_NN be_VB used_VBN for_IN ART_NP ._SENT French_JJ authorities_NNS have_VBP recently_RB recommended_VBN a_DT similar_JJ algorithm_NN ._SENT Since_IN HCV_NP loads_NNS can_MD vary_VB dramatically_RB within_IN a_DT few_JJ days_NNS both_CC in_IN seminal_JJ plasma_NN and_CC in_IN spermatozoa_NNS ,_, the_DT safest_JJS approach_NN to_TO ART_NN for_IN patients_NNS exhibiting_VBG HCV_NP RNA_NP in_IN seminal_JJ plasma_NN would_MD consist_VB of_IN the_DT use_NN of_IN cryopreserved_JJ cells_NNS that_WDT tested_VBD negative_JJ at_IN the_DT time_NN of_IN sampling_NN ._SENT Although_IN the_DT uneventful_JJ deliveries_NNS of_IN infants_NNS to_TO the_DT cohort_NN evaluated_VBN in_IN the_DT present_JJ study_NN are_VBP encouraging_VBG ,_, the_DT validation_NN of_IN this_DT guideline_NN would_MD need_VB to_TO be_VB assessed_VBN with_IN a_DT larger_JJR population_NN of_IN chronically_RB infected_JJ individuals_NNS ._SENT 